Real-world dostarlimab use in advanced/recurrent endometrial cancer in France-Reference-Cited by-同舟云学术

Real-world dostarlimab use in advanced/recurrent endometrial cancer in France

Published:2023-10 Issue:10 Volume:110 Page:1041-1050
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:en
Short-container-title:Bulletin du Cancer

Author:

Rodrigues Manuel^ORCID,Eberst Lauriane,Follana Philippe,Gauthier Ludiane,Jacquemin Virginie,Tessier Christophe,El Mouaddin Nadia^ORCID,Boudier Philippe,Fiteni Frederic,Angeli Eurydice,Roche Sophie,Delanoy Nicolas,Sabatier Renaud,Flippot Ronan,de la Motte Rouge Thibault

Funder

GlaxoSmithKline Inc

GlaxoSmithKline

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference38 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J Clin,2021

2. France - Global Cancer Observatory;World Health Organization,2020

3. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Uterine Cancer;National Cancer Institute,2022

4. Endometrial tumors with MSI-H and dMMR share a similar tumor immune microenvironment;Song;Onco Targets Ther,2021

5. Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review;Lorenzi;J Oncol,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of pembrolizumab and dostarlimab in advanced endometrial carcinoma: a systematic review;Discover Medicine;2024-09-10

2. Dostarlimab/Salbutamol;Reactions Weekly;2024-07-20

3. Dostarlimab associé à la chimiothérapie dans le cancer endométrial en rechute ou avancé;Bulletin du Cancer;2024-05